{'fraction_non_alphanumeric': 0.02599388379204893, 'fraction_numerical': 0.0045871559633027525, 'mean_word_length': 5.968085106382978, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Overcoming chemoresistance using tumor mitochondria-targeted photodynamic therapy

Chemoresistance is a significant challenge in the treatment of patients with ovarian cancer. An important mechanism in resistance to cisplatin is increased drug efflux from tumor cells, potentially mediated by ATPdependent factors such as the ATPases, ATP7A/ATP7B, and the ATP binding cassette (ABC) family member, MRP2. Therefore, a promising strategy to overcome chemoresistance is targeted inhibition of ATP production in tumor cells. In this work, we developed a mitochondria-targeted photodynamic therapy (PDT) approach in ovarian tumors to overcome chemoresistance.